PREFER

The patient perspective

PREFER looks at how and when it is best to perform and include patient-preference in decision making during the drug life cycle. We include patient stakeholders at every level of the project. The end-result will be recommendations to support development of guidelines for industry, Regulatory Authorities and HTA bodies.

Vikas Soekhai, PhD Student

Challenges and opportunities in patient preference assessment

Patient preferences are taking on an increasingly important role in the lifecycle of medical products. The methods to assess preferences are many, and PREFER will contribute knowledge on which methods are best suited at different points. As part of his PhD project, Vikas Soekhai will help identify methods and simulate the impact the choice of method may have on preference study results. 

Vikas Soekhai's PhD will contribute to PREFER knowledge on the challenges and opportunities involved in assessments of patient preferences throughout the whole lifecycle of drugs and medical devices.

Read interview

Isabelle Manneh-Vangramberen, ECPC

The patient voice in preference research

Patient organisations provide a strong and united patients’ voice, placing patients at the centre of EU Health policy and the forefront of research programmes. Through various Innovative Medicines Initiative (IMI) projects, including PREFER, patient advocates voices have become increasingly present in all aspects of drug development: from fundamental research to regulatory aspects, pricing and reimbursement decisions at the EU-level.

Isabelle Manneh Vangramberen, Pharmacist, Public Health Professional, EU Expert and a patient advocate at the European Cancer Patient Coalition (ECPC), leads patient input through the PREFER patient stakeholder advisory group. Here, she shares the patient perspective and her view on how it is represented in PREFER.

Read interview

Finding out what patients prefer

Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) is a five year public-private research project where academic researchers, HTA, patient organisations, and the pharmaceutical industry work together to find out when and where patients want, can, and should be involved in drug development.

We are looking forward to sharing our findings with you!

Mats G. Hansson, Uppsala University, Coordinator
Conny Berlin, Novartis, Project Leader

Mats G. Hansson, co-ordinator & Conny Berlin, project leader, PREFER